Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats
Autore:
Wardas, J; Konieczny, J; Lorenc-Koci, E;
Indirizzi:
Polish Acad Sci, Inst Pharmacol, Dept Neuropsychopharmacol, PL-31343 Krakow, Poland Polish Acad Sci Krakow Poland PL-31343 harmacol, PL-31343 Krakow, Poland
Titolo Testata:
SYNAPSE
fascicolo: 2, volume: 41, anno: 2001,
pagine: 160 - 171
SICI:
0887-4476(200108)41:2<160:S5AAAR>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
C-FOS EXPRESSION; 6-HYDROXYDOPAMINE-LESIONED RATS; MESSENGER-RNA; STRIATOPALLIDAL NEURONS; DOPAMINE INTERACTIONS; MEDIATED MODULATION; TURNING BEHAVIOR; GLOBUS-PALLIDUS; BASAL GANGLIA; STRIATUM;
Keywords:
adenosine A(2A) receptors; muscle rigidity; haloperidol; reserpine; SCH 58261; parkinsonism;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
48
Recensione:
Indirizzi per estratti:
Indirizzo: Wardas, J Polish Acad Sci, Inst Pharmacol, Dept Neuropsychopharmacol, 12 Smetna St, PL-31343 Krakow, Poland Polish Acad Sci 12 Smetna St Krakow Poland PL-31343 kow, Poland
Citazione:
J. Wardas et al., "SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats", SYNAPSE, 41(2), 2001, pp. 160-171

Abstract

The aim of the present study was to find out whether blockade of adenosineA(2A) receptors by a selective antagonist, SCH 58261, influenced parkinsonian-like muscle rigidity. Muscle tone was examined using a combined mechano- and electromyographic method which simultaneously measured muscle resistance (MMG) of a rat hindfoot to passive extension and flexion in the ankle joint and electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior. Muscle rigidity produced by reserpine (5 mg/kg + alpha -methyl-p-tyrosine, 250 mg/kg) was antagonized by SCH 58261 (0.1-5 mg/kg). SCH 58261 (5 mg/kg) also reduced reserpine-enhanced tonic and reflex EMG activities in both the gastrocnemius and the tibialis muscles. Moreover, SCH 58261 in doses of 1 and 5 mg/kg abolished muscleresistance induced by haloperidol (0.5 mg/kg). However, only the highest dose of SCH 58261 (5 mg/kg) decreased tonic EMG activity enhanced by haloperidol. Administration of L-DOPA (75 and 100 mg/kg) dose-dependently decreased the muscle resistance as well as tonic EMG activity evoked by haloperidol. Combined administration of SCH 58261 (0.1 mg/kg) and L-DOPA (50 mg/kg) indoses which did not affect the haloperidol-induced muscle rigidity produced a pronounced synergistic effect. The ability of SCH 58261 to diminish theparkinsonian-like muscle rigidity and to potentiate the effect of L-DOPA in this model seems to indicate a therapeutic value of this compound in the treatment of Parkinson's disease. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/06/19 alle ore 17:59:54